medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2022-16-16-50-56medsovet-7089Research ArticleРЕПРОДУКТИВНОЕ ЗДОРОВЬЕ И ВРТREPRODUCTIVE HEALTH AND ARTПрименение мио-инозитола у женщин с синдромом поликистозных яичников при вспомогательных репродуктивных технологияхUse of myo-inositol in women with polycystic ovary syndrome in the application of auxiliary reproductive technologiesТитоваМ. С.TitovaM. S.

Маргарита Сергеевна Титова, студентка

Институт «Медицинская академия имени С. И. Георгиевского»

2-ой медицинский факультет

4-ый курс

295051

бульвар Ленина, д. 5/7

Республика Крым

Симферополь

Margarita S. Titova, 4th Year Student

Institute “Medical Academy named after S. I. Georgievsky

2nd Faculty of Medicine

295051

5/7, Lenin Boulevard

Republic of Crimea

Simferopol

titova.margo00@mail.ruКолодинаМ. И.KolodinaM. I.

Мария Ивановна Колодина, студентка

Институт «Медицинская академия имени С. И. Георгиевского»

2-ой медицинского факультет

5-ый курс

295051

бульвар Ленина, д. 5/7

Республика Крым

Симферополь

Maria I. Kolodina, 5th Year Student

Institute “Medical Academy named after S. I. Georgievsky

2nd Faculty of Medicine

295051

5/7, Lenin Boulevard

Republic of Crimea

Simferopol

kolodinamariauvanovna@mail.ruЛяшенкоА. С.LyashenkoA. S.

Анастасия Сергеевна Ляшенко, студентка

6-ой курс 

195067

Пискаревский проспект, д. 47

Санкт- Петербург

Anastasiya S. Lyashenko, 6th Year Student

195067

47, Piskarevsky Ave.

St Petersburg

grobovaya98@mail.ruЛяшенкоЕ. Н.LyashenkoE. N.

Елена Николаевна Ляшенко, к. м. н., доцент

Институт «Медицинская академия имени С. И. Георгиевского»

кафедра акушерства и гинекологии № 2

295051

бульвар Ленина, д. 5/7

Республика Крым

Симферополь

Elena N. Lyashenko, Cand. Sci. (Med.), Associate Professor

Institute “Medical Academy named after S. I. Georgievsky

Department of Obstetrics and Gynecology No. 2

295051

5/7, Lenin Boulevard

Republic of Crimea

Simferopol

helen.lyashen@mail.ruКрымский федеральный университет имени В. И. ВернадскогоРоссияCrimean Federal University named after V. I. VernadskyRussian FederationСеверо-Западный государственный медицинский университет имени И. И. МечниковаРоссияNorth-Western State Medical University named after I. I. MechnikovRussian Federation2022071020220165056Copyright © Титова М.С., Колодина М.И., Ляшенко А.С., Ляшенко Е.Н., 20222022Титова М.С., Колодина М.И., Ляшенко А.С., Ляшенко Е.Н.Titova M.S., Kolodina M.I., Lyashenko A.S., Lyashenko E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7089

   Введение. В настоящее время рассматривается большое количество методов лечения женщин с синдромом поликистозных яичников (СПКЯ). Одним из новых подходов к терапии СПКЯ является лечение мио-инозитолом.

   Цель работы – изучить влияние мио-инозитола на восстановление репродуктивной функции у женщин с СПКЯ при вспомогательных репродуктивных технологиях.   Материалы и методы. Нами был проведен систематический поиск и анализ научных работ в базах PubMed, MEDLINE, Embase, eLIBRARY, «КиберЛенинка» и Google Scholar с использованием поисковых терминов «СПКЯ», «терапия мио-инозитолом» и «вспомогательные репродуктивные технологии при СПКЯ».   Результаты и обсуждение. В развитии СПКЯ в 30–40 % случаев играют роль инсулинорезистентность и гиперандрогения. Мио-инозитол, являющийся эндогенным метаболитом организма человека, участвует в синтезе инозитолфосфатных производных, которые необходимы для передачи сигнала от рецепторов инсулина, гонадотропин-рилизинг-гормона, лютеинизирующего и фолликулостимулирующего гормона. Данное вещество способствует увеличению чувствительности к инсулину, что позволяет снизить гиперандрогению и улучшить менструальный цикл. Нами был проведен анализ литературы о применении мио-инозитола у женщин с СПКЯ при вспомогательных репродуктивных технологиях, так как он эффективен в нормализации функции яичников, улучшении качества ооцитов и эмбрионов при СПКЯ.   Заключение. Проанализированные исследования показывают улучшение функций яичников, качества яйцеклеток и эмбрионов на фоне приема мио-инозитола в его комбинации с другими препаратами. Однако необходим дальнейший анализ крупных многоцентровых рандомизированных контролируемых исследований для оценки беременности и живорождаемости, так как существуют источники, которые не подтверждают эффективность терапии мио-инозитолом.

   Introduction

   Introduction. A large number of treatments for women with PCOS are currently under consideration. Treatment with myo-inositol is one of the new approaches to the treatment of PCOS.

   Aim

   Aim. To study the effect of myo-inositol on the restoration of reproductive function in women with polycystic ovary syndrome using assisted reproductive technologies.   Materials and methods. We conducted a systematic search and analysis of scientific papers in PubMed, MEDLINE, Embase, eLIBRARY, CyberLeninka and Google Scholar using the search PCOS, myo-inositol therapy and assisted reproductive technologies in PCOS terms.   Results and discussion. In the development of PCOS, insulin resistance and hyperandrogenism play a role in 30–40 % of cases. Myo-inositol, which is an endogenous metabolite of the human body, is involved in the synthesis of inositol phosphate derivatives, which are necessary for signal transmission from insulin, GnRH, LH, FSH receptors. This substance helps to increase insulin sensitivity, which can reduce hyperandrogenism and improve the menstrual cycle. We analyzed the literature on the use of MI in women with PCOS with assisted reproductive technologies, since Myo-inositol is effective in normalizing ovarian function, improving the quality of oocytes and embryos in PCOS.   Conclusion. The studies we examined show improvements in ovarian function, oocyte and embryo quality in patients taking myo-inositol combined with other drugs. However, further examination of large multicenter, randomized, controlled studies are needed to evaluate pregnancy and live births, as there are sources that do not confirm the efficacy of myo-inositol therapy.

вспомогательные репродуктивные технологииинсулинорезистентностьбеременностьсиндром овариальной дисфункцииметаболический синдромassisted reproductive technologiesinsulin resistancepregnancyovarian dysfunction syndromemetabolic syndromeReferencesAzziz R., Woods K. S., Reyna R., Key T. J., Knochenhauer E. S., Yildiz B. O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89 (6): 2745–2749. https://doi.org/10.1210/jc.2003-032046.Azziz R., Woods K. S., Reyna R., Key T. J., Knochenhauer E. S., Yildiz B. O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89 (6): 2745–2749. https://doi.org/10.1210/jc.2003-032046.Yildiz B. O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27 (10): 3067–3073. https://doi.org/10.1093/humrep/des232.Yildiz B. O., Bozdag G., Yapici Z., Esinler I., Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012; 27 (10): 3067–3073. https://doi.org/10.1093/humrep/des232.Teede H. J., Misso M. L., Costello M. F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence- based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 89 (3): 251–268. https://doi.org/10.1111/cen.13795.Teede H. J., Misso M. L., Costello M. F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence- based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 89 (3): 251–268. https://doi.org/10.1111/cen.13795.Lizneva D., Suturina L., Walker W., Brakta S., Gavrilova- Jordan L., Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106 (1): 6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003.Lizneva D., Suturina L., Walker W., Brakta S., Gavrilova- Jordan L., Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 106 (1): 6–15. https://doi.org/10.1016/j.fertnstert.2016.05.003.Lizneva D., Kirubakaran R., Mykhalchenko K., Suturina L., Chernukha G., Diamond M. P., Azziz R. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016; 106 (6): 1510–1520.e2. https://doi.org/10.1016/j.fertnstert.2016.07.1121.Lizneva D., Kirubakaran R., Mykhalchenko K., Suturina L., Chernukha G., Diamond M. P., Azziz R. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016; 106 (6): 1510–1520.e2. https://doi.org/10.1016/j.fertnstert.2016.07.1121.Belenkaia L. V., Lazareva L. M., Walker W., Lizneva D. V., Suturina L. V. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol. 2019; 71 (3): 211–223. URL: https://www.researchgate.net/publication/333111051_Criteria_phenotypes_and_prevalence_of_polycystic_ovary_syndromeBelenkaia L. V., Lazareva L. M., Walker W., Lizneva D. V., Suturina L. V. Criteria, phenotypes and prevalence of polycystic ovary syndrome. Minerva Ginecol. 2019; 71 (3): 211–223. URL: https://www.researchgate.net/publication/333111051_Criteria_phenotypes_and_prevalence_of_polycystic_ovary_syndromeСоснова Е. А. Синдром поликистозных яичников / Е. А. Соснова // Архив акушерства и гинекологии им. В. Ф. Снегирева. – 2016. – (3): 116–129. https://doi.org/10.18821/2313-8726-2016-3-3-116-129. – Sosnova E. A. Polycystic ovary syndrome. V. F. Snegirev Archives of Obstetrics and Gynecology. 2016; (3): 116–129. (In Russ.) https://doi.org/10.18821/2313-8726-2016-3-3-116-129.Соснова Е. А. Синдром поликистозных яичников / Е. А. Соснова // Архив акушерства и гинекологии им. В. Ф. Снегирева. – 2016. – (3): 116–129. https://doi.org/10.18821/2313-8726-2016-3-3-116-129. – Sosnova E. A. Polycystic ovary syndrome. V. F. Snegirev Archives of Obstetrics and Gynecology. 2016; (3): 116–129. (In Russ.) https://doi.org/10.18821/2313-8726-2016-3-3-116-129.Deswal R., Nanda S., Ghalaut V. S., Roy P. S., Dang A. S. Cross-sectional study of the prevalence of polycystic ovary syndrome in rural and urban populations. Int J Gynaecol Obstet. 2019; 146 (3): 370–379. https://doi.org/10.1002/ijgo.12893.Deswal R., Nanda S., Ghalaut V. S., Roy P. S., Dang A. S. Cross-sectional study of the prevalence of polycystic ovary syndrome in rural and urban populations. Int J Gynaecol Obstet. 2019; 146 (3): 370–379. https://doi.org/10.1002/ijgo.12893.Fauser B. C., Tarlatzis B. C., Rebar R. W., Legro R. S., Balen A. H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE / ASRM-Sponsored 3 rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024.Fauser B. C., Tarlatzis B. C., Rebar R. W., Legro R. S., Balen A. H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE / ASRM-Sponsored 3 rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024.Wolf W. M., Wattick R. A., Kinkade O. N., Olfert M. D. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race / Ethnicity. Int J Environ Res Public Health. 2018; 15 (11): 2589. https://doi.org/10.3390/ijerph15112589.Wolf W. M., Wattick R. A., Kinkade O. N., Olfert M. D. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race / Ethnicity. Int J Environ Res Public Health. 2018; 15 (11): 2589. https://doi.org/10.3390/ijerph15112589.Knochenhauer E. S., Key T. J., Kahsar-Miller M., Waggoner W., Boots L. R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83 (9): 3078–3082. https://doi.org/10.1210/jcem.83.9.5090.Knochenhauer E. S., Key T. J., Kahsar-Miller M., Waggoner W., Boots L. R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998; 83 (9): 3078–3082. https://doi.org/10.1210/jcem.83.9.5090.Артымук Н. В. Новое о патогенезе и лечении синдрома поликистозных яичников / Н. В. Артымук, О. А. Тачкова // РМЖ. Мать и дитя. – 2021. – 4 (1): 17–22. https://doi.org/10.32364/2618-8430-2021-4-1-17-22. – Artymuk N. V., Tachkova O. A. New about the pathogenesis and treatment of polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2021; 4 (1): 17–22. (In Russ.) https://doi.org/10.32364/2618-8430-2021-4-1-17-22.Артымук Н. В. Новое о патогенезе и лечении синдрома поликистозных яичников / Н. В. Артымук, О. А. Тачкова // РМЖ. Мать и дитя. – 2021. – 4 (1): 17–22. https://doi.org/10.32364/2618-8430-2021-4-1-17-22. – Artymuk N. V., Tachkova O. A. New about the pathogenesis and treatment of polycystic ovary syndrome. Russian Journal of Woman and Child Health. 2021; 4 (1): 17–22. (In Russ.) https://doi.org/10.32364/2618-8430-2021-4-1-17-22.Goodman N. F., Cobin R. H., Futterweit W., Glueck J. S., Legro R. S., Carmina E. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 2. Endocr Pract. 2015; 21 (12): 1415–1426. https://doi.org/10.4158/EP15748.DSCPT2.Goodman N. F., Cobin R. H., Futterweit W., Glueck J. S., Legro R. S., Carmina E. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome – part 2. Endocr Pract. 2015; 21 (12): 1415–1426. https://doi.org/10.4158/EP15748.DSCPT2.Azziz R., Carmina E., Chen Z., Dunaif A., Laven J. S., Legro R. S. et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2: 16057. https://doi.org/10.1038/nrdp.2016.57.Azziz R., Carmina E., Chen Z., Dunaif A., Laven J. S., Legro R. S. et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2: 16057. https://doi.org/10.1038/nrdp.2016.57.Carvalho M. J., Subtil S., Rodrigues Â., Oliveira J., Figueiredo-Dias M. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol. 2019; 243: 125–132. https://doi.org/10.1016/j.ejogrb.2019.10.011.Carvalho M. J., Subtil S., Rodrigues Â., Oliveira J., Figueiredo-Dias M. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol. 2019; 243: 125–132. https://doi.org/10.1016/j.ejogrb.2019.10.011.Meczekalski B., Pérez-Roncero G. R., López-Baena M. T., Chedraui P., Pérez-López F. R. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020; 36 (4): 289–293. https://doi.org/10.1080/09513590.2020.1730794.Meczekalski B., Pérez-Roncero G. R., López-Baena M. T., Chedraui P., Pérez-López F. R. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020; 36 (4): 289–293. https://doi.org/10.1080/09513590.2020.1730794.Wen Y., Wu X., Peng H., Li C., Jiang Y., Su Z. et al. Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis. Breast Cancer Res Treat. 2021; 185 (3): 799–806. https://doi.org/10.1007/s10549-020-05973-z.Wen Y., Wu X., Peng H., Li C., Jiang Y., Su Z. et al. Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis. Breast Cancer Res Treat. 2021; 185 (3): 799–806. https://doi.org/10.1007/s10549-020-05973-z.Громова О. А. Роли мио-инозитола в поддержании репродуктивного здоровья женщины / О. А. Громова [и др.] // Повышение эффективности технологий экстракорпорального оплодотворения // РМЖ. Мать и дитя. – 2018. – 1(1): 88–95. https://doi.org/10.32364/2618-8430-2018-1-1-88-95. – Gromova O. A., Torshin I. Yu., Kalacheva A. G., Tetruashvili N. K. Roles of myo-in-ositol in maintaining women’s reproductive health. Increase effectiveness of in vitro fertilization techniques. Russian Journal of Woman and Child Health. 2018; 1 (1): 88–95. (In Russ.) https://doi.org/10.32364/2618-8430-2018-1-1-88-95.Громова О. А. Роли мио-инозитола в поддержании репродуктивного здоровья женщины / О. А. Громова [и др.] // Повышение эффективности технологий экстракорпорального оплодотворения // РМЖ. Мать и дитя. – 2018. – 1(1): 88–95. https://doi.org/10.32364/2618-8430-2018-1-1-88-95. – Gromova O. A., Torshin I. Yu., Kalacheva A. G., Tetruashvili N. K. Roles of myo-in-ositol in maintaining women’s reproductive health. Increase effectiveness of in vitro fertilization techniques. Russian Journal of Woman and Child Health. 2018; 1 (1): 88–95. (In Russ.) https://doi.org/10.32364/2618-8430-2018-1-1-88-95.Воронцова А. В. Заключение совещания экспертов «Обоснование применения средств на основе инозитола у пациенток с нарушениями менструального цикла» / А. В. Воронцова [и др.] // Проблемы репродукции. – 2020. – 26 (1): 44–54. https://doi.org/10.17116/repro20202601144. – Vorontsova A. V., Gasparyan S. A., Gromova O. A., Dzhobava M., Kiseleva E. Yu., Korotkikh I. N. et al. The conclusion of the Expert Council ‘The product rationale based on inositol for use by patients with menstrual irregularities’. Russian Journal of Human Reproduction. 2020; 26 (1): 44–54. (In Russ.) https://doi.org/10.17116/repro20202601144.Воронцова А. В. Заключение совещания экспертов «Обоснование применения средств на основе инозитола у пациенток с нарушениями менструального цикла» / А. В. Воронцова [и др.] // Проблемы репродукции. – 2020. – 26 (1): 44–54. https://doi.org/10.17116/repro20202601144. – Vorontsova A. V., Gasparyan S. A., Gromova O. A., Dzhobava M., Kiseleva E. Yu., Korotkikh I. N. et al. The conclusion of the Expert Council ‘The product rationale based on inositol for use by patients with menstrual irregularities’. Russian Journal of Human Reproduction. 2020; 26 (1): 44–54. (In Russ.) https://doi.org/10.17116/repro20202601144.Miñambres I., Cuixart G., Gonçalves A., Corcoy R. Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019; 38 (3): 1146–1152. https://doi.org/10.1016/j.clnu.2018.06.957.Miñambres I., Cuixart G., Gonçalves A., Corcoy R. Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials. Clin Nutr. 2019; 38 (3): 1146–1152. https://doi.org/10.1016/j.clnu.2018.06.957.Laganà A. S., Garzon S., Casarin J., Franchi M., Ghezzi F. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018; 29 (11): 768–780. https://doi.org/10.1016/j.tem.2018.09.001.Laganà A. S., Garzon S., Casarin J., Franchi M., Ghezzi F. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach. Trends Endocrinol Metab. 2018; 29 (11): 768–780. https://doi.org/10.1016/j.tem.2018.09.001.Chiu T. T., Rogers M. S., Law E. L., Briton-Jones C. M., Cheung L. P., Haines C. J. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002; 17 (6): 1591–1596. https://doi.org/10.1093/humrep/17.6.1591.Chiu T. T., Rogers M. S., Law E. L., Briton-Jones C. M., Cheung L. P., Haines C. J. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod. 2002; 17 (6): 1591–1596. https://doi.org/10.1093/humrep/17.6.1591.Unfer V., Carlomagno G., Rizzo P., Raffone E., Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011; 15 (4): 452–457. Available at: https://pubmed.ncbi.nlm.nih.gov/21608442.Unfer V., Carlomagno G., Rizzo P., Raffone E., Roseff S. Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Eur Rev Med Pharmacol Sci. 2011; 15 (4): 452–457. Available at: https://pubmed.ncbi.nlm.nih.gov/21608442.Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019; 23 (12): 5512–5521. https://doi.org/10.26355/eurrev_201906_18223.Nordio M., Basciani S., Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019; 23 (12): 5512–5521. https://doi.org/10.26355/eurrev_201906_18223.Громова О. А. Перспективы использования мио-инозитола в предгравидарной подготовке женщин с поликистозом яичников и инсулинорезистентностью / О. А. Громова [и др.] // Гинекология. – 2014. – 16 (1): 58–65. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/28298. – Gromova O. A., Goncharova E. A., Torshin I. Yu., Limanova O. A., Kerimkulova N. V. Myo-inositol pregravidal training use prospects in women with polycystic ovary syndrome and insulin resistance. Gynecology. 2014; 16 (1): 58–65. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28298/.Громова О. А. Перспективы использования мио-инозитола в предгравидарной подготовке женщин с поликистозом яичников и инсулинорезистентностью / О. А. Громова [и др.] // Гинекология. – 2014. – 16 (1): 58–65. Режим доступа: https://gynecology.orscience.ru/2079-5831/article/view/28298. – Gromova O. A., Goncharova E. A., Torshin I. Yu., Limanova O. A., Kerimkulova N. V. Myo-inositol pregravidal training use prospects in women with polycystic ovary syndrome and insulin resistance. Gynecology. 2014; 16 (1): 58–65. (In Russ.) Available at: https://gynecology.orscience.ru/2079-5831/article/view/28298/.Zacchè M. M., Caputo L., Filippis S., Zacchè G., Dindelli M., Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25 (8): 508–513. https://doi.org/10.1080/09513590903015544.Zacchè M. M., Caputo L., Filippis S., Zacchè G., Dindelli M., Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009; 25 (8): 508–513. https://doi.org/10.1080/09513590903015544.Minozzi M., D’Andrea G., Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online. 2008; 17 (4): 579–582. https://doi.org/10.1016/s1472-6483(10)60248-9.Minozzi M., D’Andrea G., Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online. 2008; 17 (4): 579–582. https://doi.org/10.1016/s1472-6483(10)60248-9.Merviel P., Bouée S., Ménard M., Le Martelot M. T., Roche S., Lelièvre C. et al. Quelles stimulations pour quelles femmes : le syndrome des ovaires polykystiques (SOPK). Gynecol Obstet Fertil Senol. 2017; 45 (11): 623–631. https://doi.org/10.1016/j.gofs.2017.10.001.Merviel P., Bouée S., Ménard M., Le Martelot M. T., Roche S., Lelièvre C. et al. Quelles stimulations pour quelles femmes : le syndrome des ovaires polykystiques (SOPK). Gynecol Obstet Fertil Senol. 2017; 45 (11): 623–631. https://doi.org/10.1016/j.gofs.2017.10.001.Papaleo E., Unfer V., Baillargeon J. P., De Santis L., Fusi F., Brigante C. et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007; 23 (12): 700–703. https://doi.org/10.1080/09513590701672405.Papaleo E., Unfer V., Baillargeon J. P., De Santis L., Fusi F., Brigante C. et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007; 23 (12): 700–703. https://doi.org/10.1080/09513590701672405.Papaleo E., Unfer V., Baillargeon J. P., Fusi F., Occhi F., De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009; 91 (5): 1750–174. https://doi.org/10.1016/j.fertnstert.2008.01.088.Papaleo E., Unfer V., Baillargeon J. P., Fusi F., Occhi F., De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril. 2009; 91 (5): 1750–174. https://doi.org/10.1016/j.fertnstert.2008.01.088.Colazingari S., Treglia M., Najjar R., Bevilacqua A. The combined therapy myo-in-ositol plus D-chiro-inositol, rather than D-chiro- inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288 (6): 1405–1411. https://doi.org/10.1007/s00404-013-2855-3.Colazingari S., Treglia M., Najjar R., Bevilacqua A. The combined therapy myo-in-ositol plus D-chiro-inositol, rather than D-chiro- inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013; 288 (6): 1405–1411. https://doi.org/10.1007/s00404-013-2855-3.Pacchiarotti A., Carlomagno G., Antonini G., Pacchiarotti A. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2016; 32 (1): 69–73. https://doi.org/10.3109/09513590.2015.1101444.Pacchiarotti A., Carlomagno G., Antonini G., Pacchiarotti A. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome. Gynecol Endocrinol. 2016; 32 (1): 69–73. https://doi.org/10.3109/09513590.2015.1101444.Mendoza N., Pérez L., Simoncini T., Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017; 35 (5): 529–535. https://doi.org/10.1016/j.rbmo.2017.07.005.Mendoza N., Pérez L., Simoncini T., Genazzani A. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017; 35 (5): 529–535. https://doi.org/10.1016/j.rbmo.2017.07.005.Laganà A. S., Vitagliano A., Noventa M., Ambrosini G., D’Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018; 298 (4): 675–684. https://doi.org/10.1007/s00404-018-4861-y.Laganà A. S., Vitagliano A., Noventa M., Ambrosini G., D’Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018; 298 (4): 675–684. https://doi.org/10.1007/s00404-018-4861-y.Zheng X., Lin D., Zhang Y., Lin Y., Song J., Li S., Sun Y. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017; 96 (49): e8842. https://doi.org/10.1097/MD.0000000000008842.Zheng X., Lin D., Zhang Y., Lin Y., Song J., Li S., Sun Y. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine (Baltimore). 2017; 96 (49): e8842. https://doi.org/10.1097/MD.0000000000008842.Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011; 95 (8): 2515–2516. https://doi.org/10.1016/j.fertnstert.2011.05.027.Carlomagno G., Unfer V., Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril. 2011; 95 (8): 2515–2516. https://doi.org/10.1016/j.fertnstert.2011.05.027.Chiu T. T., Rogers M. S., Briton-Jones C., Haines C. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod. 2003; 18 (2): 408–416. https://doi.org/10.1093/humrep/deg113.Chiu T. T., Rogers M. S., Briton-Jones C., Haines C. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod. 2003; 18 (2): 408–416. https://doi.org/10.1093/humrep/deg113.Akbari Sene A., Tabatabaie A., Nikniaz H., Alizadeh A., Sheibani K., Mortezapour Alisaraie M. et al. The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet. 2019; 299 (6): 1701–1707. https://doi.org/10.1007/s00404-019-05111-1.Akbari Sene A., Tabatabaie A., Nikniaz H., Alizadeh A., Sheibani K., Mortezapour Alisaraie M. et al. The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial. Arch Gynecol Obstet. 2019; 299 (6): 1701–1707. https://doi.org/10.1007/s00404-019-05111-1.Mendoza N., Diaz-Ropero M. P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019; 35 (8): 695–700. https://doi.org/10.1080/09513590.2019.1576620.Mendoza N., Diaz-Ropero M. P., Aragon M., Maldonado V., Llaneza P., Lorente J. et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019; 35 (8): 695–700. https://doi.org/10.1080/09513590.2019.1576620.Mendoza N., Galan M. I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2020; 36 (5): 398–401. https://doi.org/10.1080/09513590.2019.1681959.Mendoza N., Galan M. I., Molina C., Mendoza-Tesarik R., Conde C., Mazheika M. et al. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2020; 36 (5): 398–401. https://doi.org/10.1080/09513590.2019.1681959.Bhide P., Pundir J., Gudi A., Shah A., Homburg R., Acharya G. The effect of myo-inositol/di-chiro- inositol on markers of ovarian reserve in women with PCOS undergoing IVF / ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019; 98 (10): 1235–1244. https://doi.org/10.1111/aogs.13625.Bhide P., Pundir J., Gudi A., Shah A., Homburg R., Acharya G. The effect of myo-inositol/di-chiro- inositol on markers of ovarian reserve in women with PCOS undergoing IVF / ICSI: A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019; 98 (10): 1235–1244. https://doi.org/10.1111/aogs.13625.Showell M. G., Mackenzie-Proctor R., Jordan V., Hodgson R., Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018; 12 (12): CD012378. https://doi.org/10.1002/14651858.CD012378.pub2.Showell M. G., Mackenzie-Proctor R., Jordan V., Hodgson R., Farquhar C. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2018; 12 (12): CD012378. https://doi.org/10.1002/14651858.CD012378.pub2.Raffone E., Rizzo P., Benedetto V. Insulin sensitiser agents alone and in co-treatment with r- FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010; 26 (4): 275–280. https://doi.org/10.3109/09513590903366996.Raffone E., Rizzo P., Benedetto V. Insulin sensitiser agents alone and in co-treatment with r- FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010; 26 (4): 275–280. https://doi.org/10.3109/09513590903366996.Agrawal A., Mahey R., Kachhawa G., Khadgawat R., Vanamail P., Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019; 35 (6): 511–514. https://doi.org/10.1080/09513590.2018.1549656.Agrawal A., Mahey R., Kachhawa G., Khadgawat R., Vanamail P., Kriplani A. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019; 35 (6): 511–514. https://doi.org/10.1080/09513590.2018.1549656.

The authors declare that there are no conflicts of interest present.